Page last updated: 2024-10-17

salicylic acid and Lichen Planus

salicylic acid has been researched along with Lichen Planus in 95 studies

Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).

Lichen Planus: An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.

Research Excerpts

ExcerptRelevanceReference
"When lichen planus involves the scalp, it is known as lichen planopilaris, and when it involves the eye, it is known as ocular lichen planus; both are rare."4.98Pediatric ocular lichen planus and lichen planopilaris: One new case and a review of the literature. ( Bevans, SL; Fowler, PG; Pavlidakey, PG; Sami, N; Stoll, M; Theos, AJ, 2018)
"The most important hair diseases are divided in non- cicatricial and cicatricial ones."2.72Common causes of hair loss - clinical manifestations, trichoscopy and therapy. ( Alessandrini, A; Bruni, F; Piraccini, BM; Starace, M, 2021)
"Analyzing other scarring diseases (lichen planopilaris, fibrotic kidney disease and scleroderma) may help to clarify the mechanism of scarring in CCCA."2.66A proposed mechanism for central centrifugal cicatricial alopecia. ( Alexander, T; Beamer, V; McMichael, A; Subash, J, 2020)
"The result is a permanent scarring hair loss accentuated at the front hairline with backward movement towards the neck mostly accompanied by a typical loss of the eyebrows."2.58[Postmenopausal lichen planopilaris also known as fibrosing frontotemporal alopecia Kossard : An evidence-oriented practical guide to treatment from the University of the Saarland, Hair Research Center of the Dr. Rolf M. Schwiete Foundation]. ( Christmann, R; Lehr, CM; Loretz, B; Mawlood, D; Müller, C; Reichrath, J; Schäfer, U; Schilling, L; Thomas, C; Vogt, T, 2018)
"Folliculitis keloidalis is a cicatricial alopecia with a mixed inflammatory infiltrate."2.52Primary scarring alopecias. ( Ioannides, D; Rigopoulos, D; Stamatios, G, 2015)
"Sarcoidosis is an idiopathic multisystem inflammatory disease that can affect virtually any part of the body."1.91Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series. ( Hosler, GA; Khalid, I; Ogwumike, E; Sode, T, 2023)
"Mucosal lichen planus was found in four patients (21."1.62Lichen planopilaris in men: a retrospective clinicopathologic study of 19 patients. ( Cantwell, HM; Imhof, RL; Proffer, SL; Tolkachjov, SN; Torgerson, RR; Wieland, CN, 2021)
"Six patients had progression of their hair loss in spite of treatment."1.62Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study. ( Bhoyrul, B; Jerjen, R; Pinczewski, J; Sinclair, R, 2021)
"Alopecia is one of these."1.56Eosinophilic folliculitis of the scalp associated with PD-1/PDL1 inhibitors. ( Carlesimo, M; Caro, G; De Vincentiis, L; Federico, A; Fortuna, MC; Magri, F; Rossi, A; Soda, G, 2020)
"One patient had hair loss of the upper cutaneous lip."1.46Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. ( Camilleri, MJ; Chaudhry, HM; Tolkachjov, SN; Torgerson, RR, 2017)
"A new subtype of LPP mimicking androgenetic alopecia (AGA) may be misdiagnosed."1.43A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. ( Abbasi, A; Abbasi, S; Kamyab-Hesari, K; Mollaee, F; Rabbani, R, 2016)
"Imiquimod 5% cream is an immune-response-modifying drug with antiviral and anti-tumour activity."1.42Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome. ( Argenziano, G; Drummond, A; Lallas, A; Longo, C; Moscarella, E; Piana, S; Pichler, J; Zalaudek, I, 2015)
"FFA is an increasingly common form of scarring hair loss, but the origin remains unknown."1.39Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. ( Bazakas, A; Ladizinski, B; Olsen, EA; Selim, MA, 2013)
"Lichen planopilaris (LPP) and pseudopelade of Brocq (PPB) are two scarring alopecia diagnoses that exhibit similar clinical features."1.36Lichen planopilaris and pseudopelade of Brocq involve distinct disease associated gene expression patterns by microarray. ( Bell, RH; Haegert, A; Isaac-Renton, M; Lo, BK; Martinka, M; McElwee, KJ; Ross, EK; Shapiro, J; Yu, M, 2010)
"However, eyebrow loss and hair loss in other body sites may also occur; this has been documented clinically, but rarely histopathologically."1.36Expanding the spectrum of frontal fibrosing alopecia: a unifying concept. ( Bashir, SJ; Chew, AL; Fenton, DA; Stefanato, CM; Wain, EM, 2010)
"All had frontotemporal recession with scarring."1.35Frontal fibrosing alopecia: clinical presentations and prognosis. ( Messenger, AG; Tan, KT, 2009)
"In 1885 Brocq described a type of scarring alopecia he called pseudopelade (PPB), whose character as a separate disease entity has been denied in recent decades."1.28[The Brocq pseudopelade--a disease picture or disease entity]. ( Bergner, T; Braun-Falco, O; Heilgemeir, GP, 1989)

Research

Studies (95)

TimeframeStudies, this research(%)All Research%
pre-199012 (12.63)18.7374
1990's7 (7.37)18.2507
2000's6 (6.32)29.6817
2010's34 (35.79)24.3611
2020's36 (37.89)2.80

Authors

AuthorsStudies
SHATIN, H1
CANIZARES, O1
WORTHINGTON, EL1
Frew, D1
Oaxaca, G1
Habermehl, G1
Unwala, R1
Bergfeld, W6
Shahidi-Dadras, M1
Asadi Kani, Z1
Dadkhahfar, S1
Zartab, H1
Rakhshan, A1
Arasu, A1
Meah, N2
Marzola, M1
Sinclair, R4
Blume-Peytavi, U2
Hillmann, K1
Constantinou, A1
Vogt, A2
Pathoulas, JT4
Flanagan, KE4
Su, MY1
Elmariah, SB1
Zhan, Y1
Walker, CJ4
Burns, LJ1
Manatis-Lornell, A1
Penzi, L1
Miller, DD1
Hordinsky, MK7
Senna, MM4
Kępińska, K1
Jałowska, M1
Bowszyc-Dmochowska, M1
Saad, S1
Cavelier-Balloy, B1
Smadja, J1
Assouly, P1
Reygagne, P2
Miteva, M2
Nadji, M1
Billero, V1
LaSenna, C1
Nattkemper, L1
Romanelli, P1
Collins, MS3
Ali, S3
Pupo Wiss, IM3
Cotsarelis, G4
Milbar, H3
Huang, K3
Mostaghimi, A3
Scott, D3
Han, JJ3
Lee, KJ3
Farah, RS3
Bellefeuille, G3
Raymond, O3
Ranasinghe, G3
Shapiro, J6
Lo Sicco, KI3
Gutierrez, D3
Ko, J3
Mirmirani, P5
Mesinkovska, N3
Yale, KL3
Goldberg, LJ3
Tosti, A6
Gwillim, EC3
Goh, C3
Karim, N1
Durbin-Johnson, BP1
Rocke, DM1
Salemi, M1
Phinney, BS1
Rice, RH1
Sode, T1
Ogwumike, E1
Hosler, GA1
Khalid, I1
Orlando, G1
Salmaso, R1
Piaserico, S1
Ramot, Y1
Bertolini, M1
Boboljova, M1
Uchida, Y1
Paus, R3
Harries, M3
Hardman, J1
Chaudhry, I1
Poblet, E3
Griggs, J1
Trüeb, RM2
Gavazzoni Dias, MFR1
Hordinsky, M2
Lee, JA1
Levy, DA1
Patel, KG1
Brennan, E1
Oyer, SL1
Del Duca, E2
Ruano Ruiz, J2
Pavel, AB2
Sanyal, RD1
Song, T1
Gay-Mimbrera, J2
Zhang, N2
Estrada, YD2
Peng, X1
Renert-Yuval, Y1
Phelps, RG2
Krueger, JG2
Guttman-Yassky, E2
Rossi, A1
Magri, F1
Caro, G1
Federico, A1
Fortuna, MC1
Soda, G1
De Vincentiis, L1
Carlesimo, M1
Bosch-Amate, X1
Riquelme-McLoughlin, C1
Morgado-Carrasco, D1
Rojano-Fritz, L1
Iranzo-Fernández, P1
Bhoyrul, B2
Trindade de Carvalho, L1
Wall, D1
Kurzeja, M1
Czuwara, J1
Walecka, I1
Olszewska, M1
Rudnicka, L3
Cantwell, HM1
Wieland, CN1
Proffer, SL1
Imhof, RL1
Torgerson, RR2
Tolkachjov, SN2
Mofarrah, R2
Jahani Amiri, K1
Ghasemi, M1
Alessandrini, A1
Bruni, F1
Piraccini, BM2
Starace, M1
Porriño-Bustamante, ML1
Fernández-Pugnaire, MA1
Castellote-Caballero, L1
Arias-Santiago, S1
Dubin, C1
Glickman, JW1
Chennareddy, S1
Han, J1
Dahabreh, D1
Kimmel, GW1
Singer, G1
Chowdhury, M1
Zheng, AY1
Angelov, M1
Olsen, EA2
Callender, V1
Chasapi, V1
Correia, O1
Dhurat, R1
Dlova, N1
Doche, I3
Enechukwu, N1
Grimalt, R1
Itami, S1
Khobzei, K1
Lee, WS1
Malakar, S1
Messenger, A1
McMichael, A3
Ovcharenko, Y1
Papanikou, S1
Pinto, GM1
Pirmez, R1
Roberts, J1
Saceda-Corralo, D1
Silyuk, T1
Soares, RO1
Souissi, A1
Washenik, K1
Zlotogorski, A1
Canfield, D1
Vano-Galvan, S1
Altemir, A1
Lobato-Berezo, A1
Pujol, RM1
Golińska, J1
Sar-Pomian, M1
Svigos, K1
Yin, L1
Fried, L1
Lo Sicco, K1
Bretas, TLB1
Issa, MC1
Vargas, TJ1
Sousa, MAJ1
Jerjen, R1
Pinczewski, J1
Chaudhry, HM1
Camilleri, MJ1
Liu, YS1
Jee, SH1
Chan, JL1
Sundberg, JP1
Lenzy, YM1
McMichael, AJ1
Christiano, AM2
McGregor, T1
Stenn, KS1
Sivamani, RK1
Pratt, CH1
King, LE1
Vogt, T1
Thomas, C1
Reichrath, J1
Schilling, L1
Mawlood, D1
Christmann, R1
Loretz, B1
Schäfer, U1
Lehr, CM1
Müller, C1
Dina, Y1
Okoye, GA1
Aguh, C1
Subash, J1
Alexander, T1
Beamer, V1
Batrani, M1
Kubba, A1
Kubba, R1
Bevans, SL1
Theos, AJ1
Fowler, PG1
Pavlidakey, PG1
Stoll, M1
Sami, N1
Costa-Silva, M1
Osorio, F1
Pedrosa, A1
Santos, P1
Azevedo, F1
Yang, CC1
Khanna, T1
Sallee, B1
Bordone, LA1
Romiti, R2
Valente, NS2
Wilcox, GL1
Ericson, M1
McAdams, BD1
Kushner, CJ1
Concha, JSS1
Pearson, DR1
Werth, VP1
Teramura, K1
Kato, T1
Nishikawa, J1
Nakanishi, T1
Tanaka, T1
Fujimoto, N1
Garcia-Robledo, JE1
Aragón, CC1
Nieto-Aristizábal, I1
Vásquez, S1
Montoya, C1
Tobón, GJ1
Eftekhari, H1
Azimi, SZ1
Rafiei, R1
Darjani, A1
Alizadeh, N1
Rafiei, E1
Ghadarjani, R1
Gharaei Nejad, K1
László, FG1
Delacerda, AB1
Chandler, RG1
Wells, MJ1
Vindhya, PL1
Drummond, A1
Pichler, J1
Argenziano, G1
Zalaudek, I1
Longo, C1
Lallas, A1
Piana, S1
Moscarella, E1
Chan, DV1
Kartono, F1
Ziegler, R1
Abdulwahab, N1
DiPaola, N1
Flynn, J1
Wong, HK1
Wilk, M1
Zelger, BG1
Zelger, B1
Yorulmaz, A1
Artuz, F1
Er, O1
Guresci, S1
Ekpo, FE1
Cibull, TL1
Kaminska, EC1
Rigopoulos, D1
Stamatios, G1
Ioannides, D1
Lanoue, J1
Yanofsky, VR1
Mercer, SE1
Ardigò, M1
Agozzino, M1
Franceschini, C1
Donadio, C1
Abraham, LS1
Barbieri, L1
Sperduti, I1
Berardesca, E1
González, S1
Jimenez, F2
Yeo, L1
Ormerod, AD1
Abbasi, A1
Kamyab-Hesari, K1
Rabbani, R1
Mollaee, F1
Abbasi, S1
Bomar, L1
Tandon, YK1
Somani, N1
Cevasco, NC1
Bergfeld, WF1
Tan, KT1
Messenger, AG1
Yu, M1
Bell, RH1
Ross, EK1
Lo, BK1
Isaac-Renton, M1
Martinka, M2
Haegert, A1
McElwee, KJ1
Lin, MY1
Chen, LJ1
Ma, L1
Wu, WY1
Xiang, LH1
Ghoreishi, M1
Dutz, JP1
Armenores, P1
Shirato, K1
Reid, C1
Sidhu, S1
Chew, AL1
Bashir, SJ1
Wain, EM1
Fenton, DA1
Stefanato, CM1
Binesh, F1
Parichehr, K1
Ladizinski, B1
Bazakas, A1
Selim, MA1
Stockmeier, M1
Kunte, C1
Sander, CA1
Wolff, H1
AYRES, S2
SANNICANDRO, G1
DEGOS, R1
RABUT, R1
LEFORT, P1
BORDA, JM2
FABRICIO, R1
SAN MARTIN, M1
MAZZINI, RH1
ACUSSE RUIZ, D1
Pascual, A1
Piqué, E1
Jordon, RE1
Isaac, M1
McNeely, MC1
Bayerl, C1
Moll, I1
Silvers, DN1
Katz, BE1
Young, AW1
Nayar, M1
Schomberg, K1
Dawber, RP1
Millard, PR1
Kossard, S1
Lee, MS1
Wilkinson, B1
Torricelli, R1
Smith, KJ1
Crittenden, J1
Skelton, H1
Nagy, E1
Szakály, I1
Matta, M1
Kibbi, AG1
Khattar, J1
Salman, SM1
Zaynoun, ST1
Braun-Falco, O1
Bergner, T1
Heilgemeir, GP1
Ebner, H1
Chenegin, VM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE[NCT04300296]Phase 2111 participants (Actual)Interventional2020-07-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP

Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model. (NCT04300296)
Timeframe: Baseline up to week 16

Interventionpercentage of participants (Median)
AIN457 300 mg Q4W - TP 1 - CLP Cohort44.0
Placebo - TP 1 - CLP Cohort58.2
AIN457 300 mg Q4W - TP 1 - MLP Cohort37.5
Placebo - TP 1 - MLP Cohort23.1
AIN457 300 mg Q4W - TP 1 - LPP Cohort37.6
Placebo - TP 1 - LPP Cohort30.9

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 0 scoreWeek 16 0 scoreWeek 16 1 scoreWeek 16 2 scoreWeek 16 3 scoreWeek 16 4 scoreWeek 16 5 scoreWeek 20 0 scoreWeek 20 1 scoreWeek 20 2 scoreWeek 20 3 scoreWeek 20 4 scoreWeek 20 5 scoreWeek 24 0 scoreWeek 24 1 scoreWeek 24 2 scoreWeek 24 3 scoreWeek 24 4 scoreWeek 24 5 scoreWeek 28 0 scoreWeek 28 1 scoreWeek 28 2 scoreWeek 28 3 scoreWeek 28 4 scoreWeek 28 5 scoreWeek 32 0 scoreWeek 32 1 scoreWeek 32 2 scoreWeek 32 3 scoreWeek 32 4 scoreWeek 32 5 score
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort0003340003232002242002332010422

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline 0 ScoreBaseline 1 scoreBaseline 2 scoreBaseline 3 scoreBaseline 4 scoreBaseline 5 scoreWeek 2 0 scoreWeek 2 1 scoreWeek 2 2 scoreWeek 2 3 scoreWeek 2 4 scoreWeek 2 5 scoreWeek 4 0 scoreWeek 4 1 scoreWeek 4 2 scoreWeek 4 3 scoreWeek 4 4 scoreWeek 4 5 scoreWeek 8 0 scoreWeek 8 1 scoreWeek 8 2 scoreWeek 8 3 scoreWeek 8 4 scoreWeek 8 5 scoreWeek 12 0 scoreWeek 12 1 scoreWeek 12 2 scoreWeek 12 3 scoreWeek 12 4 scoreWeek 12 5 scoreWeek 16 0 scoreWeek 16 1 scoreWeek 16 2 scoreWeek 16 3 scoreWeek 16 4 scoreWeek 16 5 score
Placebo - TP 1 - CLP Cohort000363001353000353011243012072023340

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline 0 ScoreBaseline 1 scoreBaseline 2 scoreBaseline 3 scoreBaseline 4 scoreBaseline 5 scoreWeek 2 0 scoreWeek 2 1 scoreWeek 2 2 scoreWeek 2 3 scoreWeek 2 4 scoreWeek 2 5 scoreWeek 4 0 scoreWeek 4 1 scoreWeek 4 2 scoreWeek 4 3 scoreWeek 4 4 scoreWeek 4 5 scoreWeek 8 0 scoreWeek 8 1 scoreWeek 8 2 scoreWeek 8 3 scoreWeek 8 4 scoreWeek 8 5 scoreWeek 12 0 scoreWeek 12 1 scoreWeek 12 2 scoreWeek 12 3 scoreWeek 12 4 scoreWeek 12 5 scoreWeek 16 0 scoreWeek 16 1 scoreWeek 16 2 scoreWeek 16 3 scoreWeek 16 4 scoreWeek 16 5 scoreWeek 20 0 scoreWeek 20 1 scoreWeek 20 2 scoreWeek 20 3 scoreWeek 20 4 scoreWeek 20 5 scoreWeek 24 0 scoreWeek 24 1 scoreWeek 24 2 scoreWeek 24 3 scoreWeek 24 4 scoreWeek 24 5 scoreWeek 28 0 scoreWeek 28 1 scoreWeek 28 2 scoreWeek 28 3 scoreWeek 28 4 scoreWeek 28 5 scoreWeek 32 0 scoreWeek 32 1 scoreWeek 32 2 scoreWeek 32 3 scoreWeek 32 4 scoreWeek 32 5 score
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort03665506593203883207574206773204125220612312181012306111322510313

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline n=25,12,0Week 4 n=24,11,0Week 8 n=25,11,0Week 12 n=25,12,0Week 16 n=25,12,10
Placebo - TP 1 - CLP Cohort00012

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 16 n=25,12,10Week 20 n=24,0,10Week 24 n=25,0,10Week 28 n=23,0,10Week 32 n=25,0,9
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort21111

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline n=25,12,0Week 4 n=24,11,0Week 8 n=25,11,0Week 12 n=25,12,0Week 16 n=25,12,10Week 20 n=24,0,10Week 24 n=25,0,10Week 28 n=23,0,10Week 32 n=25,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort022333432

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline n=24,13,0Week 4 n=24,13,0Week 8 n=24,13,0Week 12 n=24,13,0Week 16 n=24,13,13
Placebo - TP 1 - LPP Cohort01121

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 16 n=24,13,13Week 20 n=24,0,13Week 24 n=23,0,13Week 28 n=24,0,13Week 32 n=24,0,11
Placebo to AIN457 300 mg Q2W TP 2 - LPP Cohort13323

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline n=24,13,0Week 4 n=24,13,0Week 8 n=24,13,0Week 12 n=24,13,0Week 16 n=24,13,13Week 20 n=24,0,13Week 24 n=23,0,13Week 28 n=24,0,13Week 32 n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort033224221

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline n=24,13,0Week 4 n=24,13,0Week 8 n=24,13,0Week 12 n=24,13,0Week 16 n=24,13,11
Placebo - TP 1 - MLP Cohort01123

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 16 n=24,13,11Week 20 n=24,0,11Week 24 n=24,0,10Week 28 n=23,0,11Week 32 n=23,0,10
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort22322

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Baseline n=24,13,0Week 4 n=24,13,0Week 8 n=24,13,0Week 12 n=24,13,0Week 16 n=24,13,11Week 20 n=24,0,11Week 24 n=24,0,10Week 28 n=23,0,11Week 32 n=23,0,10
AIN457 300 mg Q4W - TP 1 and TP 2- MLP Cohort024457734

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 IGA <=2 n=25,12,0Week 2 IGA improvement >=2 n=25,12,0Week 2 IGA 0/1 n=25,12,0Week 4 IGA <=2 n=24,11,0Week 4 IGA improvement. >=2 n=24,11,0Week 4 IGA 0/1 n=24,11,0Week 8 IGA <=2 n=25,11,0Week 8 IGA improvement. >=2 n=25,11,0Week 8 IGA 0/1 n=25,11,0Week 12 IGA <=2 n=25,12,0Week 12 IGA improvement. >=2 n=25,12,0Week 12 IGA 0/1 n=25,12,0Week16 IGA <=2 n=25,12,10Week 16 IGA improvement. >=2 n=25,12,10Week 16 IGA 0/1 n=25,12,10
Placebo - TP 1 - CLP Cohort100200311421732

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week16 IGA <=2 n=25,12,10Week 16 IGA improvement. >=2 n=25,12,10Week 16 IGA 0/1 n=25,12,10Week 20 IGA <=2 n=24,0,10Week 20 IGA improvement. >=2 n=24,0,10Week 20 IGA 0/1 n=24,0,10Week 24 IGA <=2 n=25,0,10Week 24 IGA improvement. >=2 n=25,0,10Week 24 IGA 0/1 n=25,0,10Week 28 IGA <=2 n=23,0,10Week 28 IGA improvement. >=2 n=23,0,10Week 28 IGA 0/1 n=23,0,10Week 32 IGA <=2 n=24,0,9Week 32 IGA improvement. >=2 n=24,0,9Week 32 IGA 0/1 n=24,0,9
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort510111321411221

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 IGA <=2 n=25,12,0Week 2 IGA improvement >=2 n=25,12,0Week 2 IGA 0/1 n=25,12,0Week 4 IGA <=2 n=24,11,0Week 4 IGA improvement. >=2 n=24,11,0Week 4 IGA 0/1 n=24,11,0Week 8 IGA <=2 n=25,11,0Week 8 IGA improvement. >=2 n=25,11,0Week 8 IGA 0/1 n=25,11,0Week 12 IGA <=2 n=25,12,0Week 12 IGA improvement. >=2 n=25,12,0Week 12 IGA 0/1 n=25,12,0Week16 IGA <=2 n=25,12,10Week 16 IGA improvement. >=2 n=25,12,10Week 16 IGA 0/1 n=25,12,10Week 20 IGA <=2 n=24,0,10Week 20 IGA improvement. >=2 n=24,0,10Week 20 IGA 0/1 n=24,0,10Week 24 IGA <=2 n=25,0,10Week 24 IGA improvement. >=2 n=25,0,10Week 24 IGA 0/1 n=25,0,10Week 28 IGA <=2 n=23,0,10Week 28 IGA improvement. >=2 n=23,0,10Week 28 IGA 0/1 n=23,0,10Week 32 IGA <=2 n=24,0,9Week 32 IGA improvement. >=2 n=24,0,9Week 32 IGA 0/1 n=24,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort52293210431034114411551410101276976

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 IGA <=2 n=24,13,0Week 2 IGA improvement >=2 n=24,13,0Week 2 IGA 0/1 n=24,13,0Week 4 IGA <=2 n=24,13,0Week 4 IGA improvement. >=2 n=24,13,0Week 4 IGA 0/1 n=24,13,0Week 8 IGA <=2 n=24,13,0Week 8 IGA improvement. >=2 n=24,13,0Week 8 IGA 0/1 n=24,13,0Week 12 IGA <=2 n=24,13,0Week 12 IGA improvement. >=2 n=24,13,0Week 12 IGA 0/1 n=24,13,0Week16 IGA <=2 n=24,13,13Week 16 IGA improvement. >=2 n=24,13,13Week 16 IGA 0/1 n=24,13,13
Placebo - TP 1 - LPP Cohort100211311422400

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week16 IGA <=2 n=24,13,13Week 16 IGA improvement. >=2 n=24,13,13Week 16 IGA 0/1 n=24,13,13Week 20 IGA <=2 n=24,0,13Week 20 IGA improvement. >=2 n=24,0,13Week 20 IGA 0/1 n=24,0,13Week 24 IGA <=2 n=23,0,13Week 24 IGA improvement. >=2 n=23,0,13Week 24 IGA 0/1 n=23,0,13Week 28 IGA <=2 n=24,0,13Week 28 IGA improvement. >=2 n=24,0,13Week 28 IGA 0/1 n=24,0,13Week 32 IGA <=2 n==24,0,11Week 32 IGA improvement. >=2 n==24,0,11Week 32 IGA 0/1 n==24,0,11
Placebo to AIN457 300 mg Q2W - TP 2- LPP Cohort400610832943754

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 IGA <=2 n=24,13,0Week 2 IGA improvement >=2 n=24,13,0Week 2 IGA 0/1 n=24,13,0Week 4 IGA <=2 n=24,13,0Week 4 IGA improvement. >=2 n=24,13,0Week 4 IGA 0/1 n=24,13,0Week 8 IGA <=2 n=24,13,0Week 8 IGA improvement. >=2 n=24,13,0Week 8 IGA 0/1 n=24,13,0Week 12 IGA <=2 n=24,13,0Week 12 IGA improvement. >=2 n=24,13,0Week 12 IGA 0/1 n=24,13,0Week16 IGA <=2 n=24,13,13Week 16 IGA improvement. >=2 n=24,13,13Week 16 IGA 0/1 n=24,13,13Week 20 IGA <=2 n=24,0,13Week 20 IGA improvement. >=2 n=24,0,13Week 20 IGA 0/1 n=24,0,13Week 24 IGA <=2 n=23,0,13Week 24 IGA improvement. >=2 n=23,0,13Week 24 IGA 0/1 n=23,0,13Week 28 IGA <=2 n=24,0,13Week 28 IGA improvement. >=2 n=24,0,13Week 28 IGA 0/1 n=24,0,13Week 32 IGA <=2 n==24,0,11Week 32 IGA improvement. >=2 n==24,0,11Week 32 IGA 0/1 n==24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort4119228338329321064107610651154

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 IGA <=2 n=24,12,0Week 2 IGA improvement >=2 n=24,12,0Week 2 IGA 0/1 n=24,12,0Week 4 IGA <=2 n=24,13,0Week 4 IGA improvement. >=2 n=24,13,0Week 4 IGA 0/1 n=24,13,0Week 8 IGA <=2 n=24,13,0Week 8 IGA improvement. >=2 n=24,13,0Week 8 IGA 0/1 n=24,13,0Week 12 IGA <=2 n=24,13,0Week 12 IGA improvement. >=2 n=24,13,0Week 12 IGA 0/1 n=24,13,0Week16 IGA <=2 n=24,13,11Week 16 IGA improvement. >=2 n=24,13,11Week 16 IGA 0/1 n=24,13,11
Placebo - TP 1 - MLP Cohort311211321442332

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week16 IGA <=2 n=24,13,11Week 16 IGA improvement. >=2 n=24,13,11Week 16 IGA 0/1 n=24,13,11Week 20 IGA <=2 n=24,0,11Week 20 IGA improvement. >=2 n=24,0,11Week 20 IGA 0/1 n=24,0,11Week 24 IGA <=2 n=24,0,10Week 24 IGA improvement. >=2 n=24,0,10Week 24 IGA 0/1 n=24,0,10Week 28 IGA <=2 n=23,0,11Week 28 IGA improvement. >=2 n=23,0,11Week 28 IGA 0/1 n=23,0,11Week 32 IGA <=2 n=23,0,10Week 32 IGA improvement. >=2 n=23,0,10Week 32 IGA 0/1 n=23,0,10
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort110321420430210

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

InterventionParticipants (Count of Participants)
Week 2 IGA <=2 n=24,12,0Week 2 IGA improvement >=2 n=24,12,0Week 2 IGA 0/1 n=24,12,0Week 4 IGA <=2 n=24,13,0Week 4 IGA improvement. >=2 n=24,13,0Week 4 IGA 0/1 n=24,13,0Week 8 IGA <=2 n=24,13,0Week 8 IGA improvement. >=2 n=24,13,0Week 8 IGA 0/1 n=24,13,0Week 12 IGA <=2 n=24,13,0Week 12 IGA improvement. >=2 n=24,13,0Week 12 IGA 0/1 n=24,13,0Week16 IGA <=2 n=24,13,11Week 16 IGA improvement. >=2 n=24,13,11Week 16 IGA 0/1 n=24,13,11Week 20 IGA <=2 n=24,0,11Week 20 IGA improvement. >=2 n=24,0,11Week 20 IGA 0/1 n=24,0,11Week 24 IGA <=2 n=24,0,10Week 24 IGA improvement. >=2 n=24,0,10Week 24 IGA 0/1 n=24,0,10Week 28 IGA <=2 n=23,0,11Week 28 IGA improvement. >=2 n=23,0,11Week 28 IGA 0/1 n=23,0,11Week 32 IGA <=2 n=23,0,10Week 32 IGA improvement. >=2 n=23,0,10Week 32 IGA 0/1 n=23,0,10
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort51141150055495410551033711922

Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline n=24,13,13Week 16 n=24,13,13
Placebo - TP 1 - LPP Cohort5.95-2.24

Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline n=24,13,13Week 16 n=24,13,13Week 32 n=24,0,13
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort5.92-1.44-2.44
Placebo to AIN457 300 mg Q2W TP 2 - Lpp Cohort5.95-2.24-3.20

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline - Question 1Week 16 Severity of itch during past 24 hours n=25,12,10Baseline- Question 2Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10Baseline- Question 3Week 16 How bothered by Itch during past 24 hours n=25,12,10
Placebo - TP 1 - CLP Cohort5.7-2.36.3-2.76.1-2.7

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline - Question 1Week 16 Severity of itch during past 24 hours n=25,12,10Week 32 Severity of itch during past 24 hours n=25,0,9Baseline- Question 2Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9Baseline- Question 3Week 16 How bothered by Itch during past 24 hours n=25,12,10Week 32 How bothered by Itch during past 24 hours n=25,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort5.1-0.8-1.55.6-0.9-1.34.8-1.0-1.1
Placebo to AIN457 300 mg Q2W TP 2 - CLP Cohort5.8-2.0-1.15.9-1.9-1.26.1-2.4-1.2

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline - Question 1 n=24,13,13Week 16 Severity of itch during past 24 hours n=24,13,11Baseline - Question 2 n=24,13,13Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13Baseline - Question 3 n=24,13,11Week 16 How bothered by Itch during past 24 hours n=24,13,13
Placebo - TP 1 - LPP Cohort3.8-1.14.2-1.33.2-1.2

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline - Question 1 n=24,13,13Week 16 Severity of itch during past 24 hours n=24,13,11Week 32 Severity of itch during past 24 hours n=24,0,11Baseline - Question 2 n=24,13,13Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11Baseline - Question 3 n=24,13,11Week 16 How bothered by Itch during past 24 hours n=24,13,13Week 32 How bothered by Itch during past 24 hours n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort4.5-0.5-1.65.1-0.7-1.84.0-0.4-1.7
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort3.8-1.1-2.44.1-1.3-2.63.2-1.2-2.2

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline - Question 1 n=23,13,11Week 16 Severity of itch during past 24 hours n=23,13,11Baseline - Question 2 n=23,13,11Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11Baseline - Question 3 n=24,13,11Week 16 How bothered by Itch during past 24 hours n=23,13,11
Placebo - TP 1 - MLP Cohort3.8-0.23.60.44.00.1

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline - Question 1 n=23,13,11Week 16 Severity of itch during past 24 hours n=23,13,11Week 32 Severity of itch during past 24 hours n=22,0,10Baseline - Question 2 n=23,13,11Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11Week 32 How severe was itch at worst moment during past 24 hours n=22,0,10Baseline - Question 3 n=24,13,11Week 16 How bothered by Itch during past 24 hours n=23,13,11Week 32 How bothered by Itch during past 24 hours n=22,0,10
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort2.50.30.12.40.80.33.4-0.5-0.2
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort4.3-0.3-0.44.10.40.44.50.0-0.4

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline - Question 1 n=25,12,10Week 16 Severity of pain during past 24 hours n=25,12,10Baseline - Question 2 n=25,12,10Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10Baseline - Question 3 n=25,12,10Week 16 How bothered by pain during past 24 hour n=25,12,10
Placebo - TP 1 - CLP Cohort3.4-0.83.9-1.23.7-0.6

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline - Question 1 n=25,12,10Week 16 Severity of pain during past 24 hours n=25,12,10Week 32 Severity of pain during past 24 hours n=25,0,9Baseline - Question 2 n=25,12,10Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9Baseline - Question 3 n=25,12,10Week 16 How bothered by pain during past 24 hour n=25,12,10Week 32 How bothered by pain during past 24 hours n=25, 0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort1.090.2-0.32.20.1-0.42.10.1-0.2
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort3.5-0.8-0.33.9-1.0-0.43.80.5-0.3

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline - Question 1 n=24,13,12Week 16 Severity of pain during past 24 hours n=24,13,12Baseline - Question 2 24,13,12Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12Baseline - Question 3 n=24,13,12Week 16 How bothered by pain during past 24 hour n=24,13,12
Placebo - TP 1 - LPP Cohort2.0-0.52.5-0.92.4-1.1

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline - Question 1 n=24,13,12Week 16 Severity of pain during past 24 hours n=24,13,12Week 32 Severity of pain during past 24 hours n=24,0,11Baseline - Question 2 24,13,12Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11Baseline - Question 3 n=24,13,12Week 16 How bothered by pain during past 24 hour n=24,13,12Week 32 How bothered by pain during past 24 hours n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort2.50.3-0.62.80.2-0.82.70.0-0.8
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort2.0-0.5-1.52.5-0.9-2.02.4-1.1-1.9

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline - Question 1 n=24,13,11Week 16 Severity of pain during past 24 hours n=24,13,11Baseline - Question 2 n=24,13,11Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11Baseline - Question 3 n=24,13,11Week 16 How bothered by pain during past 24 hour n=24,13,11
Placebo - TP 1 - MLP Cohort5.9-0.16.4-0.36.5-0.3

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline - Question 1 n=24,13,11Week 16 Severity of pain during past 24 hours n=24,13,11Week 32 Severity of pain during past 24 hours n=23,0,10Baseline - Question 2 n=24,13,11Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10Baseline - Question 3 n=24,13,11Week 16 How bothered by pain during past 24 hour n=24,13,11Week 32 How bothered by pain during past 24 hours n=23,0,10
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort5.1-0.5-0.35.4-0.5-0.35.5-0.8-0.5
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort6.30.0-0.66.7-0.2-0.56.8-0.1-0.9

Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline n=24,13,12Week 16 n=24,13,12
Placebo - TP 1 - LPP Cohort54.01-6.94

Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline n=24,13,12Week 16 n=24,13,12Week 32 n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 -LPP Cohort55.751.86-4.26
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort54.01-6.94-14.43

Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline n=21,12,10Week 16 n=21,12,10
Placebo - TP 1 - MLP Cohort13.40.8

Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline n=21,12,10Week 16 n=21,12,10Week 32 n=20,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort11.0-1.0-1.8
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort13.9-0.4-0.7

Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Interventionscores on a scale (Mean)
Baseline n=21,12,10Week 16 n=21,12,10
Placebo - TP 1 - MLP Cohort25.29-5.79

Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

,
Interventionscores on a scale (Mean)
Baseline n=21,12,10Week 16 n=21,12,10Week 32 n=20,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort21.31-4.83-6.08
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort26.95-4.10-2.17

Reviews

15 reviews available for salicylic acid and Lichen Planus

ArticleYear
[Frontal fibrosing alopecia-update].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2022, Volume: 73, Issue:5

    Topics: Adolescent; Alopecia; Eyebrows; Female; Fibrosis; Humans; Inflammation; Lichen Planus; Male; Scalp

2022
Frontal Fibrosing Alopecia - a review and a practical guide for clinicians.
    Annals of agricultural and environmental medicine : AAEM, 2022, Jun-24, Volume: 29, Issue:2

    Topics: Alopecia; Child, Preschool; Female; Forehead; Humans; Hydroxychloroquine; Lichen Planus; Scalp

2022
PPAR-γ signalling as a key mediator of human hair follicle physiology and pathology.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Alopecia; Animals; Cicatrix; Epithelial-Mesenchymal Transition; Hair; Hair Diseases; Hair Follicle;

2020
Fibrosing alopecia in a pattern distribution.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:6

    Topics: Alopecia; Female; Fibrosis; Hair Follicle; Humans; Lichen Planus; Male; Middle Aged; Scalp

2021
Hair Transplantation in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Systematic Review.
    The Laryngoscope, 2021, Volume: 131, Issue:1

    Topics: Alopecia; Dermoscopy; Hair; Humans; Lichen Planus; Scalp

2021
Common causes of hair loss - clinical manifestations, trichoscopy and therapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:3

    Topics: Alopecia; Alopecia Areata; Hair Diseases; Humans; Lichen Planus; Scalp; Trichotillomania

2021
Diagnostic Accuracy of Trichoscopy in Inflammatory Scalp Diseases: A Systematic Review.
    Dermatology (Basel, Switzerland), 2022, Volume: 238, Issue:3

    Topics: Dermatitis, Contact; Dermatitis, Seborrheic; Dermoscopy; Humans; Lichen Planus; Lupus Erythematosus,

2022
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris.
    American journal of clinical dermatology, 2021, Volume: 22, Issue:5

    Topics: Humans; Lichen Planus; Scalp; Scalp Dermatoses

2021
[Postmenopausal lichen planopilaris also known as fibrosing frontotemporal alopecia Kossard : An evidence-oriented practical guide to treatment from the University of the Saarland, Hair Research Center of the Dr. Rolf M. Schwiete Foundation].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2018, Volume: 69, Issue:2

    Topics: Adult; Aged; Algorithms; Alopecia; Diagnosis, Differential; Evidence-Based Medicine; Female; Fibrosi

2018
A proposed mechanism for central centrifugal cicatricial alopecia.
    Experimental dermatology, 2020, Volume: 29, Issue:2

    Topics: Alopecia; Cicatrix; Fibrosis; Humans; Kidney; Kidney Diseases; Lichen Planus; PPAR gamma; Scalp; Scl

2020
Pediatric ocular lichen planus and lichen planopilaris: One new case and a review of the literature.
    Pediatric dermatology, 2018, Volume: 35, Issue:6

    Topics: Child; Cyclosporine; Eye; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lichen Planus;

2018
Graham-Little-Piccardi-Lasseur syndrome: case report and review of the syndrome in men.
    International journal of dermatology, 2014, Volume: 53, Issue:8

    Topics: Abnormalities, Multiple; Adult; Alopecia; Axilla; Cicatrix; Darier Disease; Eyebrows; Humans; Lichen

2014
Primary scarring alopecias.
    Current problems in dermatology, 2015, Volume: 47

    Topics: Acne Keloid; Alopecia; Cellulitis; Cicatrix; Fibrosis; Folliculitis; Humans; Lichen Planus; Lupus Er

2015
Dermatitis herpetiformis associated with lichen planopilaris.
    Journal of the American Academy of Dermatology, 1995, Volume: 33, Issue:6

    Topics: Autoimmune Diseases; Biopsy; Chronic Disease; Dermatitis Herpetiformis; Humans; Lichen Planus; Male;

1995
[Hair casts in lichen ruber].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1993, Volume: 44, Issue:1

    Topics: Antifungal Agents; Diagnosis, Differential; Drug Therapy, Combination; Hair; Humans; Lichen Planus;

1993

Other Studies

80 other studies available for salicylic acid and Lichen Planus

ArticleYear
Lichen planus-like drug eruption due to para-amino salicylic acid; report of 5 cases, two showing mouth lesions.
    The Journal of investigative dermatology, 1953, Volume: 21, Issue:3

    Topics: Aminosalicylic Acid; Drug Eruptions; Humans; Lichen Planus; Mouth; Mouth Diseases; Salicylic Acid; T

1953
Plasma Cell-Predominant Lichen Planopilaris.
    The American Journal of dermatopathology, 2022, Feb-01, Volume: 44, Issue:2

    Topics: Alopecia; Hair Follicle; Humans; Lichen Planus; Male; Middle Aged; Plasma Cells; Scalp

2022
The presence of mast cells in lichen planopilaris and discoid lupus erythematosus of the scalp: A quantitative study.
    Journal of cutaneous pathology, 2022, Volume: 49, Issue:5

    Topics: Alopecia; Cell Count; Humans; Lichen Planus; Lupus Erythematosus, Discoid; Mast Cells; Scalp

2022
Scalp reduction surgery does not reactivate frontal fibrosing alopecia: A case report.
    Dermatologic therapy, 2022, Volume: 35, Issue:6

    Topics: Alopecia; Humans; Lichen Planus; Plastic Surgery Procedures; Scalp

2022
A prospective pilot study of narrowband UV-B treatment of lichen planopilaris.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:3

    Topics: Alopecia; Humans; Lichen Planus; Pilot Projects; Prospective Studies; Scalp

2022
Inflammatory complications after hair transplantation: Report of 10 cases.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Alopecia; Eczema; Female; Hair; Humans; Lichen Planus; Male; Scalp

2022
IL-17 Expression in the Perifollicular Fibrosis in Biopsies From Lichen Planopilaris.
    The American Journal of dermatopathology, 2022, Dec-01, Volume: 44, Issue:12

    Topics: Alopecia; Biopsy; Cicatrix; Fibrosis; Humans; Interleukin-17; Lichen Planus; Retrospective Studies;

2022
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Male; Scalp; United States

2023
Protein profiling of forehead epidermal corneocytes distinguishes frontal fibrosing from androgenetic alopecia.
    PloS one, 2023, Volume: 18, Issue:3

    Topics: Alopecia; Epidermis; Fibrosis; Forehead; Humans; Lichen Planus; Scalp; Skin

2023
Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series.
    The American Journal of dermatopathology, 2023, Jul-01, Volume: 45, Issue:7

    Topics: Alopecia; Alopecia Areata; Cicatrix; Humans; Lichen Planus; Sarcoidosis; Scalp

2023
A Case of Secondary Osteoma Cutis Associated with Lichen Planopilaris.
    Acta dermato-venereologica, 2019, Nov-01, Volume: 99, Issue:12

    Topics: Alopecia; Bone Diseases, Metabolic; Clobetasol; Female; Glucocorticoids; Humans; Hydroxychloroquine;

2019
Profiling the human hair follicle immune system in lichen planopilaris and frontal fibrosing alopecia: can macrophage polarization differentiate these two conditions microscopically?
    The British journal of dermatology, 2020, Volume: 183, Issue:3

    Topics: Alopecia; Hair Follicle; Humans; Lichen Planus; Macrophages; Scalp

2020
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing.
    The British journal of dermatology, 2020, Volume: 183, Issue:6

    Topics: Alopecia; Alopecia Areata; Humans; Janus Kinase 3; Lichen Planus; Quality of Life; Scalp

2020
Eosinophilic folliculitis of the scalp associated with PD-1/PDL1 inhibitors.
    Journal of cosmetic dermatology, 2020, Volume: 19, Issue:12

    Topics: Alopecia; Folliculitis; Humans; Immune Checkpoint Inhibitors; Lichen Planus; Programmed Cell Death 1

2020
Report of two cases of mucous membrane pemphigoid with frontal fibrosing alopecia: a variant of lichen planus pemphigoides or an incidental finding?
    Clinical and experimental dermatology, 2020, Volume: 45, Issue:6

    Topics: Aged; Alopecia; Female; Gingivitis; Humans; Lichen Planus; Mouth Diseases; Mouth Mucosa; Pemphigoid,

2020
Cicatricial pattern hair loss is not a variant of lichen planopilaris.
    Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:6

    Topics: Alopecia; Humans; Lichen Planus; Scalp

2020
Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab.
    Dermatologic therapy, 2020, Volume: 33, Issue:4

    Topics: Alopecia; Antibodies, Monoclonal, Humanized; Cicatrix; Fibrosis; Humans; Lichen Planus; Scalp

2020
Features of classic lichen planopilaris and frontal fibrosing alopecia in reflectance confocal microscopy: A preliminary study.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2021, Volume: 27, Issue:2

    Topics: Alopecia; Hair Follicle; Humans; Lichen Planus; Microscopy, Confocal; Scalp

2021
Lichen planopilaris in men: a retrospective clinicopathologic study of 19 patients.
    International journal of dermatology, 2021, Volume: 60, Issue:4

    Topics: Alopecia; Clobetasol; Female; Humans; Lichen Planus; Male; Retrospective Studies; Scalp

2021
Co-localization of alopecia areata and lichen planopilaris in a patient receiving immunosuppressants: A rare case.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:3

    Topics: Adult; Alopecia; Alopecia Areata; Female; Hair Follicle; Humans; Immunosuppressive Agents; Lichen Pl

2021
Colour Doppler ultrasound study in patients with frontal fibrosing alopecia.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2021, Volume: 27, Issue:5

    Topics: Alopecia; Cross-Sectional Studies; Female; Fibrosis; Humans; Lichen Planus; Scalp; Ultrasonography,

2021
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.
    Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:3

    Topics: Alopecia; Alopecia Areata; Biomarkers; Cross-Sectional Studies; Female; Fibrosis; Humans; Lichen Pla

2022
Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).
    The British journal of dermatology, 2021, Volume: 185, Issue:6

    Topics: Alopecia; Cicatrix; Clinical Trials as Topic; Consensus; Guidelines as Topic; Humans; Lichen Planus;

2021
Scalp demodicosis developing in a patient with frontal fibrosing alopecia: a clinical and trichoscopic mimicker of active disease.
    International journal of dermatology, 2022, Volume: 61, Issue:4

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Scalp

2022
Flushing episodes in the context of frontal fibrosing alopecia with facial papules.
    BMJ case reports, 2021, Aug-05, Volume: 14, Issue:8

    Topics: Alopecia; Female; Forehead; Humans; Lichen Planus; Retrospective Studies; Scalp

2021
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:12

    Topics: Alopecia; Alopecia Areata; Female; Humans; Lichen Planus; Middle Aged; Retrospective Studies; Scalp;

2021
Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases.
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:4

    Topics: Adult; Aged; Alopecia; Anti-Inflammatory Agents; Cheek; Cicatrix; Clobetasol; Dermatologic Agents; E

2017
Hair transplantation for the treatment of lichen planopilaris and frontal fibrosing alopecia: A report of two cases.
    The Australasian journal of dermatology, 2018, Volume: 59, Issue:2

    Topics: Adult; Alopecia; Female; Fibrosis; Forehead; Hair; Humans; Lichen Planus; Middle Aged; Scalp

2018
Cicatricial Alopecia Research Foundation meeting, May 2016: Progress towards the diagnosis, treatment and cure of primary cicatricial alopecias.
    Experimental dermatology, 2018, Volume: 27, Issue:3

    Topics: Alopecia; Animals; Cicatrix; Disease Models, Animal; Dogs; Fibrosis; Humans; Lichen Planus; Mice; Sc

2018
The timing and distribution of nonscalp hair loss in patients with lichen planopilaris and frontal fibrosing alopecia: A survey-based study.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:2

    Topics: Alopecia; Female; Fibrosis; Humans; Lichen Planus; Middle Aged; Scalp; Self Report; Time Factors

2021
Lichen planopilaris beyond scalp: a case series with dermoscopy-histopathology correlation.
    International journal of dermatology, 2018, Volume: 57, Issue:11

    Topics: Adult; Dermoscopy; Female; Humans; Lichen Planus; Male; Middle Aged; Scalp; Scalp Dermatoses

2018
Scalp porocarcinoma and lichen planopilaris.
    Dermatology online journal, 2018, Jul-15, Volume: 24, Issue:7

    Topics: Adult; Eccrine Porocarcinoma; Female; Hair Follicle; Head and Neck Neoplasms; HIV Infections; Humans

2018
Tofacitinib for the treatment of lichen planopilaris: A case series.
    Dermatologic therapy, 2018, Volume: 31, Issue:6

    Topics: Administration, Oral; Adult; Aged; Alopecia; Dermatologic Agents; Drug Administration Schedule; Fema

2018
"Normal-appearing" scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Biopsy; Dermatology; Female; Fibrosis; Humans; Inflammatio

2020
Evidence for neurogenic inflammation in lichen planopilaris and frontal fibrosing alopecia pathogenic mechanism.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Biopsy; Calcitonin Gene-Related Peptide; Chronic Disease;

2020
Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:3

    Topics: Aged; Alopecia; Diagnosis, Differential; Female; Fibrosis; Humans; Lichen Planus; Lupus Erythematosu

2019
Oral lichen planus and lichen planopilaris complicated with thymoma.
    The Journal of dermatology, 2019, Volume: 46, Issue:7

    Topics: Aged; Alopecia; Biopsy; Cobalt; Female; Hair Follicle; Humans; Lichen Planus; Lichen Planus, Oral; M

2019
Frontal fibrosing alopecia: A new autoimmune entity?
    Medical hypotheses, 2019, Volume: 124

    Topics: Adult; Aged; Alopecia; Animals; Autoimmune Diseases; Cicatrix; Female; Fibrosis; Humans; Lichen Plan

2019
Dermoscopic features of lichen planopilaris in Northern Iran: a prospective observational study.
    International journal of dermatology, 2019, Volume: 58, Issue:12

    Topics: Adult; Alopecia; Biopsy; Cicatrix; Dermoscopy; Feasibility Studies; Female; Hair; Hair Diseases; Hum

2019
Isolated linear lichen planopilaris: extremely rare when limited to the scalp.
    Cutis, 2013, Volume: 92, Issue:6

    Topics: Adult; Cicatrix; Follow-Up Studies; Forehead; Humans; Lichen Planus; Male; Scalp

2013
Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.
    The Australasian journal of dermatology, 2015, Volume: 56, Issue:4

    Topics: Alopecia; Aminoquinolines; Antineoplastic Agents; Basal Cell Nevus Syndrome; Drug Eruptions; Female;

2015
Absence of HLA-DR1 positivity in 2 familial cases of frontal fibrosing alopecia.
    Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:5

    Topics: Alopecia; Antibodies; Female; Fibrosis; HLA-DR1 Antigen; Humans; Lichen Planus; Middle Aged; Scalp;

2014
Lichen planopilaris with foreign-body granuloma.
    The American Journal of dermatopathology, 2015, Volume: 37, Issue:1

    Topics: Alopecia; Biopsy; Fibrosis; Granuloma, Foreign-Body; Hair Follicle; Humans; Lichen Planus; Male; Mid

2015
A case of Graham-Little-Piccardi-Lasseur syndrome.
    Dermatology online journal, 2015, Jun-16, Volume: 21, Issue:6

    Topics: Aged; Alopecia; Axilla; Female; Groin; Humans; Lichen Planus; Scalp; Syndrome

2015
Violaceous Eruption on the Head and Extremities. Lichen Planus Actinicus.
    JAMA dermatology, 2015, Volume: 151, Issue:10

    Topics: Biopsy; Extremities; Humans; Lichen Planus; Male; Middle Aged; Scalp

2015
The Use of Anti-Keratin 903 Antibodies to Visualize Colloid Bodies and Diagnose Lichen Planopilaris.
    The American Journal of dermatopathology, 2016, Volume: 38, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies; Antibodies, Monoclonal, Murine-Derived; Biomar

2016
Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment.
    Archives of dermatological research, 2016, Volume: 308, Issue:5

    Topics: Alopecia Areata; Biopsy; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Humans; Lichen Planu

2016
Frontal fibrosing alopecia: a disease fascinating for the researcher, disappointing for the clinician and distressing for the patient.
    Experimental dermatology, 2016, Volume: 25, Issue:11

    Topics: Alopecia; Fibrosis; Humans; Lichen Planus; Scalp

2016
Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:6

    Topics: Aged; Erythema; Female; Humans; Immunosuppressive Agents; Lichen Planus; Lichen Planus, Oral; Middle

2016
A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2016, Volume: 42, Issue:10

    Topics: Adult; Aged; Alopecia; Biopsy; Cross-Sectional Studies; Diagnosis, Differential; Female; Hair Follic

2016
Frontal fibrosing alopecia.
    The British journal of dermatology, 2017, Volume: 177, Issue:3

    Topics: Aged; Alopecia; Female; Fibrosis; Hair Preparations; Humans; Laser Therapy; Lichen Planus; Male; Sca

2017
A histologic review of 27 patients with lichen planopilaris.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:1

    Topics: Adult; Aged; Alopecia; Biopsy; Cicatrix; Female; Humans; Lichen Planus; Male; Middle Aged; Retrospec

2008
Frontal fibrosing alopecia: clinical presentations and prognosis.
    The British journal of dermatology, 2009, Volume: 160, Issue:1

    Topics: Adult; Aged; Alopecia; Cicatrix; Disease Progression; Eyebrows; Female; Fibrosis; Forehead; Hair Fol

2009
Lichen planopilaris and pseudopelade of Brocq involve distinct disease associated gene expression patterns by microarray.
    Journal of dermatological science, 2010, Volume: 57, Issue:1

    Topics: Alopecia; Animals; Biopsy; Cluster Analysis; False Positive Reactions; Gene Expression; Gene Express

2010
Generalized reticulated hyperpigmentation induced by lichen planus.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:8

    Topics: Aged; Diagnosis, Differential; Female; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation;

2009
Type 1 interferon signature in the scalp lesions of alopecia areata.
    The British journal of dermatology, 2010, Volume: 163, Issue:1

    Topics: Alopecia Areata; Hair Follicle; Humans; Interferon Type I; Lichen Planus; Lupus Erythematosus, Disco

2010
Frontal fibrosing alopecia associated with generalized hair loss.
    The Australasian journal of dermatology, 2010, Volume: 51, Issue:3

    Topics: Aged; Alopecia; Eyebrows; Female; Fibrosis; Hair; Humans; Lichen Planus; Middle Aged; Postmenopause;

2010
Expanding the spectrum of frontal fibrosing alopecia: a unifying concept.
    Journal of the American Academy of Dermatology, 2010, Volume: 63, Issue:4

    Topics: Adult; Age Distribution; Aged; Alopecia; Biopsy, Needle; Cohort Studies; Diagnosis, Differential; Di

2010
The follicular triad: a pathological clue to the diagnosis of early frontal fibrosing alopecia.
    The British journal of dermatology, 2012, Volume: 166, Issue:2

    Topics: Alopecia; Early Diagnosis; Fibrosis; Forehead; Humans; Lichen Planus; Middle Aged; Scalp

2012
Erosive lichen planus of the scalp and hepatitis C infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2013, Volume: 23, Issue:2

    Topics: Alopecia; Biopsy; Glucocorticoids; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Lichen

2013
Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University.
    Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Anti-Bacterial Agents; Azasteroids; Cicatrix; D

2013
[Kossard frontal fibrosing alopecia in a man].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2002, Volume: 53, Issue:6

    Topics: Aged; Alopecia; Biopsy; Fibrosis; Hair Follicle; Humans; Lichen Planus; Male; Scalp; Sex Factors

2002
Nodular neurodermatitis of the scalp.
    Australian journal of dermatology, 1951, Volume: 1, Issue:1

    Topics: Head; Humans; Lichen Planus; Neurodermatitis; Scalp

1951
[Histopathology of lichen ruber planus on the scalp].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1955, Volume: 6, Issue:9

    Topics: Disease; Head; Humans; Lichen Planus; Scalp

1955
[Pseudopelade; statistics of 109 new cases; findings on lichen planus of the scalp].
    Archives belges de dermatologie et de syphiligraphie, 1957, Volume: 13, Issue:4

    Topics: Alopecia; Biometry; Humans; Lichen Planus; Scalp

1957
[Lichen sclerosus et atrophicus of the scalp and other localizations].
    Archivos argentinos de dermatologia, 1961, Volume: 11

    Topics: Disease; Humans; Lichen Planus; Lichen Sclerosus et Atrophicus; Medical Records; Scalp; Skin Disease

1961
[Lichen of the scalp].
    Archivos argentinos de dermatologia, 1961, Volume: 11

    Topics: Disease; Exanthema; Humans; Lichen Planus; Lichens; Scalp; Skin Diseases

1961
Frontal fibrosing alopecia versus lichen planopilaris: a clinicopathological study.
    International journal of dermatology, 2006, Volume: 45, Issue:4

    Topics: Aged; Aged, 80 and over; Alopecia; Apoptosis; Biopsy; Female; Fibrosis; Fluorescent Antibody Techniq

2006
Subtle clues to diagnosis by immunopathology. Scarring alopecia.
    The American Journal of dermatopathology, 1980,Summer, Volume: 2, Issue:2

    Topics: Alopecia; Fluorescent Antibody Technique; Humans; Lichen Planus; Lupus Erythematosus, Systemic; Scal

1980
Pseudopelade of Brocq is lichen planopilaris: report of four cases that support this nosology.
    Cutis, 1993, Volume: 51, Issue:2

    Topics: Adult; Aged; Alopecia Areata; Female; Humans; Lichen Planus; Male; Middle Aged; Scalp; Scalp Dermato

1993
A clinicopathological study of scarring alopecia.
    The British journal of dermatology, 1993, Volume: 128, Issue:5

    Topics: Adult; Alopecia; Child; Child, Preschool; Female; Fibrin; Fluorescent Antibody Technique; Humans; Li

1993
Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.
    Journal of the American Academy of Dermatology, 1997, Volume: 36, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Antimalarials; Biopsy; Chloroquine; Dermato

1997
[Lichen planopilaris simulating postmenopausal frontal fibrosing alopecia (Kossard)].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1998, Volume: 49, Issue:5

    Topics: Aged; Alopecia; Diagnosis, Differential; Female; Fibrosis; Hair Follicle; Humans; Lichen Planus; Mid

1998
Lichen planopilaris-like changes arising within an epidermal nevus: does this case suggest clues to the etiology of lichen planopilaris?
    Journal of cutaneous medicine and surgery, 2000, Volume: 4, Issue:1

    Topics: Adolescent; Alopecia; Humans; Lichen Planus; Male; Nevus, Intradermal; Scalp; Skin Neoplasms

2000
[Discoid lupus erythematosus or lichen planus?].
    Zeitschrift fur Hautkrankheiten, 1978, Sep-01, Volume: 53, Issue:17

    Topics: Chloroquine; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lichen Planus; Lupus Eryth

1978
Lichen planopilaris: a clinicopathologic study.
    Journal of the American Academy of Dermatology, 1990, Volume: 22, Issue:4

    Topics: Adult; Aged; Epidermis; Epithelium; Female; Fibrosis; Humans; Hyperplasia; Lichen Planus; Male; Midd

1990
[The Brocq pseudopelade--a disease picture or disease entity].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1989, Volume: 40, Issue:2

    Topics: Adolescent; Adult; Aged; Alopecia; Child; Child, Preschool; Cicatrix; Diagnosis, Differential; Femal

1989
[Scientific session of the Munich Dermatological society Inc. and the Association of Gerfman Residential Dermatologist, Munich branch, on November 29, 1967].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1968, Volume: 19, Issue:10

    Topics: Abscess; Acanthosis Nigricans; Adult; Aged; Anus Diseases; Axilla; Carcinoma, Basal Cell; Child; Con

1968
[Lichen planus with onychatrophy and cicatricial alopecia (author's transl)].
    Dermatologica, 1973, Volume: 147, Issue:3

    Topics: Alopecia; Atrophy; Biopsy; Blister; Cicatrix; Female; Foot Dermatoses; Hallux; Humans; Lichen Planus

1973
[On the effect of the age and factors of the environment upon lichen pilaris and xeroderma].
    Vestnik dermatologii i venerologii, 1965, Volume: 39, Issue:11

    Topics: Aging; Environment; Humans; Ichthyosis; Lichen Planus; Scalp

1965